Why Iron Deficiency in Acute Heart Failure Should Be Treated: A Real-World Clinical Practice Study

<b>Background.</b> This study aims to determine whether the administration of ferric carboxymaltose (FCM) in patients with acute heart failure (AHF) and iron deficiency (ID) improves morbidity and mortality. <b>Methods.</b> We studied 890 consecutive patients admitted for AHF...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Life
المؤلفون الرئيسيون:	Raquel López-Vilella, Víctor Donoso Trenado, Pablo Jover Pastor, Ignacio Sánchez-Lázaro, Luis Martínez Dolz, Luis Almenar Bonet
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	MDPI AG 2022-11-01
الموضوعات:	acute heart failure iron deficiency ferric carboxymaltose preserved ejection fraction reduced ejection fraction morbidity
الوصول للمادة أونلاين:	https://www.mdpi.com/2075-1729/12/11/1828

مواد مشابهة

Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
حسب: Raquel López‐Vilella, وآخرون
منشور في: (2022-02-01)

Factors Predicting Myocardial Recovery After Hospitalization for De Novo Heart Failure with Reduced Left Ventricular Ejection Fraction: Results from the COMFE Registry
حسب: Víctor Donoso-Trenado, وآخرون
منشور في: (2025-05-01)

Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction
حسب: E. F. Muslimova, وآخرون
منشور في: (2025-01-01)

Biomarkers in the Pathogenesis of Heart Failure with Preserved as Well as Reduced Ejection Fraction: A Cross-sectional Study
حسب: Sowmiya Thiyagarajan, وآخرون
منشور في: (2025-06-01)

Lipoprotein(a) and Heart Failure Among Black and White Participants in Atherosclerosis Risk in Communities Study, Framingham Offspring Study, and Multi‐Ethnic Study of Atherosclerosis: The Pooling Project
حسب: Sarah Nomura, وآخرون
منشور في: (2025-06-01)

Plasma levels of free fatty acid differ in patients with left ventricular preserved, mid-range, and reduced ejection fraction
حسب: Ning Zhu, وآخرون
منشور في: (2018-05-01)

Relationship Between Dietary Magnesium Intake and Incident Heart Failure Among Older Women: The WHI
حسب: Wen‐Chih Wu, وآخرون
منشور في: (2020-04-01)

Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis
حسب: Yue Zhang, وآخرون
منشور في: (2025-09-01)

Low admission pulse pressure and increased in-hospital mortality in patients with heart failure
حسب: Liying Zhong, وآخرون
منشور في: (2026-04-01)

Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction
حسب: Shunsuke Kiuchi, وآخرون
منشور في: (2020-02-01)

Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides
حسب: Kaiyuan Zhu, وآخرون
منشور في: (2021-07-01)

Catestatin as a predictor for cardiac death in heart failure with mildly reduced and preserved ejection fraction
حسب: Song‐Yun Chu, وآخرون
منشور في: (2025-02-01)

Obesity paradox in chronic heart failure with moderately reduced or preserved left ventricular ejection fraction: impact on a prognosis for patients according to a five-year follow-up
حسب: P. P. Bidzilya, وآخرون
منشور في: (2023-07-01)

Systematic review and meta-analysis of stroke and thromboembolism risk in atrial fibrillation with preserved vs. reduced ejection fraction heart failure
حسب: Meijuan Zhang, وآخرون
منشور في: (2024-09-01)

Understanding How Heart Metabolic Derangement Shows Differential Stage Specificity for Heart Failure with Preserved and Reduced Ejection Fraction
حسب: Federico Ferro, وآخرون
منشور في: (2022-07-01)

A comparison of clinical outcomes following atrial fibrillation ablation for heart failure patients with preserved or reduced left ventricular function: A systematic review and meta-analysis
حسب: Gaurav Panchal, وآخرون
منشور في: (2022-01-01)

Axial Muscle Size as a Strong Predictor of Death in Subjects With and Without Heart Failure
حسب: Anupam Kumar, وآخرون
منشور في: (2019-02-01)

Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center Experience
حسب: Nikolina Brkić, وآخرون
منشور في: (2024-01-01)

Effect of ferric-carboxy maltose on oxygen kinetics and functional status in heart failure patients with iron deficiency
حسب: Sandip Dhoot, وآخرون
منشور في: (2020-06-01)

Interpretation of the Essential Updates in 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
حسب: Yifang GUO
منشور في: (2022-06-01)

Sirt1 Activity in PBMCs as a Biomarker of Different Heart Failure Phenotypes
حسب: Valeria Conti, وآخرون
منشور في: (2020-11-01)

Magnesium, Oxidative Stress, Inflammation, and Cardiovascular Disease
حسب: Man Liu, وآخرون
منشور في: (2020-09-01)

Heart failure. The current state of the problem: achievements, frustrations, hopes and prospects
حسب: E. F. Pavlysh, وآخرون
منشور في: (2019-04-01)

Prevalence and Long‐Term Survival After Coronary Artery Bypass Grafting in Women and Men With Heart Failure and Preserved Versus Reduced Ejection Fraction
حسب: Louise Y. Sun, وآخرون
منشور في: (2018-06-01)

Iron deficiency anemia with menorrhagia: Ferric carboxymaltose a safer alternative to blood transfusion
حسب: Vineet Mishra, وآخرون
منشور في: (2018-01-01)

Why majority of heart failure with preserved ejection fraction randomized controlled trials fail? Part: I
حسب: Satyanarayana Upadhyayula, وآخرون
منشور في: (2018-01-01)

Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus
حسب: Alexander A. Berezin, وآخرون
منشور في: (2022-09-01)

Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia
حسب: Burak Yasin Aktaş, وآخرون
منشور في: (2023-11-01)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
حسب: Lars H. Lund, وآخرون
منشور في: (2022-02-01)

Early Efficacy and Hypophosphatemia After Ferric Carboxymaltose Infusion Therapy in Patients With Iron Deficiency Anemia: A Single-Center Experience
حسب: Hana Matijaca, وآخرون
منشور في: (2026-01-01)

Efficacy and safety of intravenous ferric carboxymaltose in iron deficiency anemia; Real-life data from Turkey, a single center experience
حسب: Ali Eser, وآخرون
منشور في: (2021-06-01)

Considerations in selecting the appropriate implantable device in post-myocardial infarction syncopal patients with mild systolic dysfunction
حسب: A. Laina, وآخرون
منشور في: (2020-01-01)

Beta blockers after myocardial infarction without heart failure: time for a paradigm shift?
حسب: Katarzyna Skibicka, وآخرون
منشور في: (2025-09-01)

Left atrioventricular coupling index measured by echocardiography in heart failure with preserved ejection fraction
حسب: Hai Nguyen Ngoc Dang, وآخرون
منشور في: (2025-07-01)

Cellular and Molecular Differences between HFpEF and HFrEF: A Step Ahead in an Improved Pathological Understanding
حسب: Steven J. Simmonds, وآخرون
منشور في: (2020-01-01)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
حسب: Yi Tang, وآخرون
منشور في: (2022-10-01)

Real-world insights into empagliflozin use in heart failure across ejection fractions and patients with or without diabetes: a multicenter study from Bangladesh
حسب: Shahjada Selim, وآخرون
منشور في: (2026-03-01)

IRON-DEFICIENCY ANEMIA IN PREGNANCY: PECULIARITIES OF THERAPY
حسب: M. A. Vinogradova
منشور في: (2018-01-01)

Diabetic microvascular complications predicts non‐heart failure with reduced ejection fraction in type 2 diabetes
حسب: Mayu Tochiya, وآخرون
منشور في: (2023-04-01)

Eligibility Criteria for Ferric Carboxymaltose in Women with Iron Deficiency in Obstetrics: An Algerian Expert Consensus
حسب: Rachida Aouameur, وآخرون
منشور في: (2024-12-01)